We use cookies to collect information, and enable our website to work properly. Please tell us whether you accept cookies by clicking the button below. If you decide not to accept cookies, our site may not work as expected and some information may not be available.
Click here for more information on cookies, including how to remove them.
Somatic testing of homologous recombination repair genes in circulating tumour DNA for determination of treatment with PARP inhibitor therapy in prostate cancer.
This EQA is sponsored by MSD and AstraZeneca, and offered in collaboration with EMQN - please do not enrol with both EQA providers.
What are participants required to do?
Enrolled participants will receive details by email when an EQA is open for assessment and/or samples have been dispatched.
Participants are expected to access the instructions and information for the cases/samples online and to analyse them according to their laboratory/centre protocols.
Participants must submit their anonymised results by the deadline using their standard laboratory report or a proforma provided by GenQA. The submitted results are independently assessed for the accuracy of the analytical/genotyping results, clinical interpretation of the results (if appropriate) and clerical accuracy (including report layout and content).
What can I expect as a participant?
Every participant will receive:
An Individual Laboratory/Centre Report (ILR/ICR) with educational advice for each distribution of this EQA.
The Summary report for each distribution of this EQA which contains information regarding general findings, a summary of methodologies used, common errors, number of participants and benchmarking.
Access to a live Performance Certificate summarising your performance status for all EQAs in which you are enrolled.
Please note: EQA details may be subject to change prior to EQA distribution.
PRODUCTS
Sample type: Plasma: artificial
Testing/analysis: Testing of circulating tumour DNA for determination of treatment with PARP inhibitor therapy in prostate cancer.
NEWSLETTER SIGN UP